Tiziana Life Sciences PLC (NASDAQ:TLSA) shares hit a new 52-week low during trading on Thursday . The stock traded as low as $6.61 and last traded at $7.46, with a volume of 18162 shares. The stock had previously closed at $8.10.
WARNING: This story was first posted by BBNS and is the sole property of of BBNS. If you are viewing this story on another site, it was illegally copied and reposted in violation of U.S. and international copyright laws. The correct version of this story can be viewed at https://baseballnewssource.com/2018/12/08/tiziana-life-sciences-tlsa-hits-new-52-week-low-at-6-61/3065638.html.
Tiziana Life Sciences Company Profile (NASDAQ:TLSA)
Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of therapeutics to treat diseases in oncology and immunology in the United Kingdom. The company's product pipeline includes Milciclib (TZLS-201) that is in phase II clinical trials for epithelial thymic carcinoma and/or thymoma in patients previously treated with chemotherapy; and Foralumab (TZLS-401), a human anti-CD3 antibody, which completed phase IIa clinical trials for autoimmune and inflammatory diseases, such as non-alcoholic steatohepatitis, primary biliary cholangitis, ulcerative colitis, multiple sclerosis, autoimmune type-1 diabetes, inflammatory bowel diseases, and lupus.
Featured Article: How is an ETF different from a mutual fund?
Receive News & Ratings for Tiziana Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tiziana Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.